1-(5-Ethyl-3-methylpyridin-2-yl)piperazine → HCID 71252575, 화합물

HRID 2411613노트

반응식

HRID 2411613 반응식
[O:1]=[S:2]1(=[O:18])[CH2:6][CH2:5][CH2:4][N:3]1[C:7]1[CH:16]=[CH:15][C:10]([C:11]([O:13]C)=O)=[C:9]([CH3:17])[N:8]=1.[CH2:19]([C:21]1[CH:22]=[C:23]([CH3:33])[C:24]([N:27]2[CH2:32][CH2:31][NH:30][CH2:29][CH2:28]2)=[N:25][CH:26]=1)[CH3:20]>>[O:18]=[S:2]1(=[O:1])[CH2:6][CH2:5][CH2:4][N:3]1[C:7]1[N:8]=[C:9]([CH3:17])[C:10]([C:11]([N:30]2[CH2:31][CH2:32][N:27]([C:24]3[C:23]([CH3:33])=[CH:22][C:21]([CH2:19][CH3:20])=[CH:26][N:25]=3)[CH2:28][CH2:29]2)=[O:13])=[CH:15][CH:16]=1

참가 물질

3

반응물 2

HCID 584845781-(5-Ethyl-3-methylpyridin-2-yl)piperazineHCID 71252256HCID 71252256, 화합물

생성물 1

HCID 71252575HCID 71252575, 화합물수율 5.1%

실험 절차

Using methyl 6-(1,1-dioxo-1λ6-isothiazolidin-2-yl)-2-methylnicotinate (300 mg) described in Preparation Example 37 and 1-(5-ethyl-3-methylpyridin-2-yl)piperazine (251 mg) described in Preparation Example 81 and by the reaction and treatment in the same manner as in Example 109, the title compound (25 mg) was obtained.

후처리

  1. customdescribed in Preparation Example 81 and by the reaction and treatment in the same manner as in Example 109

출처 및 근거

ORD 기록
ord-f1716edaabfa4f969169ae9e6915e255
출처 데이터셋
uspto-grants-2014_08
특허 번호
US08816079B2

반응 노트

불러오는 중…